Cisplatin (C) and gemcitabine (G) chemotherapy with concurrent irradiation (XRT), for the conservative treatment of invasive transitional bladder cancer (ITBC) patients: Clinical outcome and long-term follow-up in a monoinstitutional experience

e16081 Background: C and G have synergistic activity when used in combination and are both potent radiosensitizers. In a dose finding trial, conducted in our hospital on ITBC patients using C and G with concurrent XRT, after maximum transurethral resection (TUR), the maximum tolerated dose of G was 400 mg/sqm (IJROBP 2003). On this basis, we have designed a phase II trial, which was prematurely closed, due to low accrual. We are presenting the...